Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412
Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical trial (NCT06414460) to evaluate…